Close Menu

More articles about Research & Discovery

Continuing its trend of doing business with suppliers who make equity investments, GeneProt last week announced it had signed an agreement with Zymark to buy four of its automated protein digestion and spotting systems Subscribers: click headline for more.

Zyomyx is off for a check-up with a diagnostics specialist: Last week, the Hayward, California-based protein chip maker said it would grant Specialty Laboratories, which offers and develops specialized clinical tests, early access to its protein biochip platform to find diagnostic protein patterns Subscribers: click headline for more.

Subscribers: click headline for more.

The challenge of getting the right formula for surface chemistry on a chip has frustrated many would-be array makers in the protein arena. How do you immobilize the ligands without allowing nonspecific binding of proteins to the chip Subscribers: click headline for more.

Subscribers: click headline for more.

The increasing availability of free public genomic data has long shed doubt on the wisdom of the genomic-database-subscription business model. Subscribers: click headline for more.

After signing DiaDexus as its second pharmaceutical partner last month, Beyond Genomics last week chose Micromass to provide liquid chromatography and mass spectrometry equipment for the systems biology company s proteomics platform. Subscribers: click headline for more.

In the world of proteomics, Europroteome chief medical officer Marc Reymond is a bit of a maverick. Subscribers: click headline for more.

Movers and Shakers/Correction

Premium

Christoph Hls, Helmut Meyer, Martin Blggel, Axel Ullrich, Holly Kleinert, Mike Sherman, Peter Chambre, John Aston. Correction: In the 2-25-02 issue of ProteoMonitor, the article, Proteomics without Pathology and Clinical Data Will Fail : Swiss Meeting, incorrectly stated that Europroteome s algorithm for predicting colorectal cancer patient prognosis was based on data collected from 135 patients. In fact, Europroteome s team of 40-odd clinicians from research hospitals across Europe compiled pathology and clinical information (134 variables) from 645 patients undergoing surgery for phase I colorectal cancer. Subscribers: click headline for more.

Industry Briefs: Mar 4, 2002

Premium

Subscribers: click headline for more.

Subscribers: click headline for more.

Drawing researchers from the UK, continental Europe, and the US, last week s IBC conference Proteomics and the Proteome in Geneva, Switzerland, painted a picture of proteomics in its most cosmopolitan of guises. Subscribers: click headline for more.

Just over two years after GeneProt s founders met in the business travelers lounge of Boston s Logan Airport to start one of the first large-scale proteomics companies, GeneProt s flagship facility in Geneva is evidence that they have made great strides towards maturity Subscribers: click headline for more.

In a talk that illustrated the plethora of proteomics technologies available for researchers with ample resources, Roche s proteomics director Hanno Langen shared new developments in his approach to separating and analyzing proteins last week at the IBC Proteomics and the Proteome conference in Geneva, Switzerland. Subscribers: click headline for more.

Subscribers: click headline for more.

Subscribers: click headline for more.

Mass-spec data-analysis software company ProteoMetrics is a shell of its former self. Subscribers: click headline for more.

Subscribers: click headline for more.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.